Table 1 Correlation analysis results between CDK1 expression and prognostic indicators
Characteristic | Level | Low expression of CDK1 | High expression of CDK1 | P value |
|---|---|---|---|---|
n | 39 | 40 | ||
T stage, n (%) | T1 | 7 (9.1%) | 2 (2.6%) | < 0.001 |
T2 | 28 (36.4%) | 14 (18.2%) | ||
T3 | 2 (2.6%) | 6 (7.8%) | ||
T4 | 2 (2.6%) | 16 (20.8%) | ||
N stage, n (%) | N0 | 36 (46.8%) | 32 (41.6%) | 0.310 |
N1 | 3 (3.9%) | 6 (7.8%) | ||
M stage, n (%) | M0 | 36 (46.8%) | 26 (33.8%) | 0.018 |
M1 | 3 (3.9%) | 12 (15.6%) | ||
Pathologic stage, n (%) | Stage I | 7 (9.1%) | 2 (2.6%) | < 0.001 |
Stage II | 25 (32.5%) | 12 (15.6%) | ||
Stage III | 4 (5.2%) | 12 (15.6%) | ||
Stage IV | 3 (3.9%) | 12 (15.6%) | ||
Tumor status, n (%) | Tumor free | 29 (37.7%) | 10 (13%) | < 0.001 |
With tumor | 10 (13%) | 28 (36.4%) | ||
Primary therapy outcome, n (%) | PD | 3 (4.5%) | 15 (22.4%) | < 0.001 |
SD | 2 (3%) | 0 (0%) | ||
PR | 1 (1.5%) | 0 (0%) | ||
CR | 32 (47.8%) | 14 (20.9%) | ||
OS event, n (%) | Alive | 35 (44.3%) | 16 (20.3%) | < 0.001 |
Dead | 4 (5.1%) | 24 (30.4%) | ||
DSS event, n (%) | Alive | 35 (45.5%) | 16 (20.8%) | < 0.001 |
Dead | 4 (5.2%) | 22 (28.6%) | ||
PFI event, n (%) | Alive | 27 (34.2%) | 11 (13.9%) | < 0.001 |
Dead | 12 (15.2%) | 29 (36.7%) |